UroGen Pharma Ltd. (URGN)

↓ Download CSV

CIK 0001668243 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated L3
  • Fiscal year ends Dec 31

In fiscal 2025, UroGen Pharma Ltd. reported revenue of $109.79M, up 21.4% from the prior year. The company ran a net loss, with a net margin of -139.8% and a gross margin of 88.7%. It held $200.46M in total assets against $305.93M in total liabilities.

Key ratios (FY2025)

88.7%
Gross margin
-113.7%
Operating margin
-139.8%
Net margin
+21.4%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$109.79M$90.40M$82.71M$64.36M$48.04M$11.80M$18.0K$1.13M$8.16M
Cost of Revenue$12.45M$8.88M$9.36M$7.65M$5.16M$1.01M$1.80M$600.0K$28.0K
Gross Profit$97.34M$81.52M$73.35M$56.70M$42.88M$10.79M$18.0K-$675.0K$7.56M$17.50M
Operating Income-$124.86M-$96.78M-$65.54M-$79.04M-$92.29M-$126.74M-$109.48M-$77.18M-$19.95M$798.0K
Net Income-$153.49M-$126.87M-$102.24M-$109.78M-$110.82M-$128.48M-$105.15M-$75.66M-$20.00M-$1.94M
EPS (Diluted)$-3.19$-2.96$-3.55$-4.81$-4.96
Total Assets$200.46M$285.71M$178.31M$135.62M$119.75M$122.00M$202.39M$103.56M$75.55M$23.06M
Total Liabilities$305.93M$294.51M$243.52M$224.98M$111.33M$25.65M$22.09M$13.46M$7.04M$6.75M
Shareholders' Equity-$105.47M-$8.80M-$65.21M-$89.36M$8.41M$96.36M$180.30M$90.09M$68.52M$16.31M
Cash & Equivalents$110.75M$171.99M$95.00M$55.41M$44.36M$52.86M$49.69M$101.32M$37.00M$21.36M
Operating Cash Flow-$162.44M-$96.77M-$76.38M-$87.56M-$84.89M-$105.89M-$71.02M-$37.33M-$9.57M$4.19M
Capital Expenditures$289.0K$295.0K$194.0K$254.0K$752.0K$1.22M$325.0K$560.0K$271.0K$695.0K
Shares Outstanding48.35M42.23M32.49M23.13M22.46M22.17M21.03M16.21M13.75M2.31M